Liu Qiang, Chairman of YaoPharma, said: "By leveraging Pfizer's exceptional global development experience and commercialisation network, along with YaoPharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to accelerate the global development and commercialisation of this innovative drug, thereby benefiting patients worldwide more rapidly and extensively." Pfizers moves with Metsera and now YaoPharma add to continued competition in the obesity drug market, which has also seen Teva Pharmaceuticals gain US Food and Drug Administration (FDA) approval in August of a generic GLP-1 of its version of Novo Nordisks injectable Saxenda (liraglutide).
Serena Williams thrilled the sports world this year with her return to the court after nearly four years away
Role of the glucagon-like-peptide-1 receptor in the control of energy balance
In the umbilical vein blood GLP-1 levels were found to be 0.7 pmol/l which is below the limit of sensitivity of the assay declared by the manufacturer of 2 pmol/l and was similar to the GLP-1 levels found in the umbilical vein blood of the control (a healthy pregnant woman not exposed to liraglutide)
In Phase 2 trials, retatrutide produced approximately 24% mean weight loss at 48 weeks at 12 mg, compared with about 22.5% for tirzepatide at 15 mg in the SURMOUNT-1 trial though direct head-to-head data is not yet available
Yes, it is designed for daily use, preferably at night, for best brightening results